| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mitchell J Riley, Colleen C Mitchell, Sarah E Ernst, Eric B Taylor, Michael J Wels. A model for stimulation of enzyme activity by a competitive inhibitor based on the interaction of terazosin and phosphoglycerate kinase 1. Proceedings of the National Academy of Sciences of the United States of America. vol 121. issue 9. 2024-02-20. PMID:38377207. |
the drug terazosin (tz) binds to and can enhance the activity of the glycolytic enzyme phosphoglycerate kinase 1 (pgk1) and can increase atp levels. |
2024-02-20 |
2024-02-23 |
Not clear |
| Karla M Opheim, Ergun Y Uc, Matthew A Cantrell, Brian C Lun. The Impact of Alpha-1-Adrenergic Receptor Antagonists on the Progression of Parkinson's Disease. Journal of the American Pharmacists Association : JAPhA. 2023-12-14. PMID:38097174. |
some aaras, such as terazosin, stimulate glycolysis and increase cellular atp levels through activation of phosphoglycerate kinase (pgk1), which has been suggested to be of therapeutic benefit in patients with parkinson's disease (pd). |
2023-12-14 |
2023-12-17 |
Not clear |
| Hao Chen, Yajie Li, Jingwen Gao, Qi Cheng, Lei Liu, Rong Ca. Activation of Pgk1 Results in Reduced Protein Aggregation in Diverse Neurodegenerative Conditions. Molecular neurobiology. 2023-05-30. PMID:37249790. |
we previously reported that terazosin (tz), a prescribed antagonist of the α1 adrenergic receptor, is an activator of phosphoglycerate kinase 1 (pgk1) and hsp90. |
2023-05-30 |
2023-08-14 |
mouse |
| Unaiza Naeem, Abdul Rehman Arshad, Areesha Jawed, Farea Eqbal, Laiba Imran, Zayeema Khan, Farhat Ija. Glycolysis: The Next Big Breakthrough in Parkinson's Disease. Neurotoxicity research. 2022-09-24. PMID:36152171. |
we highlight how terazosin (tz), via pgk1, increases atp levels and how enhanced glycolysis serves a neuroprotective role in pd, and compensates for damage caused by mitophagy. |
2022-09-24 |
2023-08-14 |
Not clear |
| Yang Wang, Shihu Qian, Fang Zhao, Yujie Wang, Jiaming L. Terazosin Analogs Targeting Pgk1 as Neuroprotective Agents: Design, Synthesis, and Evaluation. Frontiers in chemistry. vol 10. 2022-08-12. PMID:35958233. |
in this study, a series of terazosin analogs were designed and synthesized for neuroprotective effects by targeting pgk1. |
2022-08-12 |
2023-08-14 |
Not clear |
| Yang Wang, Shihu Qian, Fang Zhao, Yujie Wang, Jiaming L. Terazosin Analogs Targeting Pgk1 as Neuroprotective Agents: Design, Synthesis, and Evaluation. Frontiers in chemistry. vol 10. 2022-08-12. PMID:35958233. |
terazosin analogs targeting pgk1 as neuroprotective agents: design, synthesis, and evaluation. |
2022-08-12 |
2023-08-14 |
Not clear |
| Yang Wang, Shihu Qian, Fang Zhao, Yujie Wang, Jiaming L. Terazosin Analogs Targeting Pgk1 as Neuroprotective Agents: Design, Synthesis, and Evaluation. Frontiers in chemistry. vol 10. 2022-08-12. PMID:35958233. |
recently, terazosin (tz), a heterocyclic compound with a quinazoline core, was found to combine with phosphoglycerol kinase 1 (pgk1) and protect neurons by enhancing pgk1 activity and promoting glycolysis, thereby slowing, or preventing the neurodegeneration of pd. |
2022-08-12 |
2023-08-14 |
Not clear |
| Jingjing Liu, Wenyang Zhao, Chun Li, Tongyu Wu, Liang Han, Zhuozhou Hu, Xiangxiang Li, Jing Zhou, Xinping Che. Terazosin Stimulates Pgk1 to Remedy Gastrointestinal Disorders. International journal of molecular sciences. vol 23. issue 1. 2022-01-11. PMID:35008842. |
our results indicate that terazosin dramatically activates pgk1, and upregulates glycose metabolism, evidenced by the enhanced atp production and higher ldh enzymatic activity. |
2022-01-11 |
2023-08-13 |
mouse |
| Jingjing Liu, Wenyang Zhao, Chun Li, Tongyu Wu, Liang Han, Zhuozhou Hu, Xiangxiang Li, Jing Zhou, Xinping Che. Terazosin Stimulates Pgk1 to Remedy Gastrointestinal Disorders. International journal of molecular sciences. vol 23. issue 1. 2022-01-11. PMID:35008842. |
terazosin stimulates pgk1 to remedy gastrointestinal disorders. |
2022-01-11 |
2023-08-13 |
mouse |
| Rahul Sasane, Amy Bartels, Michelle Field, Maria I Sierra, Sridhar Duvvuri, David L Gray, Sokhom S Pin, John J Renger, David J Ston. Parkinson disease among patients treated for benign prostatic hyperplasia with α1 adrenergic receptor antagonists. The Journal of clinical investigation. vol 131. issue 11. 2021-10-04. PMID:33822767. |
backgroundrecently the α1 adrenergic receptor antagonist terazosin was shown to activate pgk1, a possible target for the mitochondrial deficits in parkinson disease related to its function as the initial enzyme in atp synthesis during glycolysis. |
2021-10-04 |
2023-08-13 |
Not clear |
| Rahul Sasane, Amy Bartels, Michelle Field, Maria I Sierra, Sridhar Duvvuri, David L Gray, Sokhom S Pin, John J Renger, David J Ston. Parkinson disease among patients treated for benign prostatic hyperplasia with α1 adrenergic receptor antagonists. The Journal of clinical investigation. vol 131. issue 11. 2021-10-04. PMID:33822767. |
an epidemiological study of terazosin users showed a lower incidence of parkinson disease when compared with users of tamsulosin, an α1 adrenergic receptor antagonist of a different class that does not activate pgk1. |
2021-10-04 |
2023-08-13 |
Not clear |
| Rong Cai, Yu Zhang, Jacob E Simmering, Jordan L Schultz, Yuhong Li, Irene Fernandez-Carasa, Antonella Consiglio, Angel Raya, Philip M Polgreen, Nandakumar S Narayanan, Yanpeng Yuan, Zhiguo Chen, Wenting Su, Yanping Han, Chunyue Zhao, Lifang Gao, Xunming Ji, Michael J Welsh, Lei Li. Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. The Journal of clinical investigation. vol 129. issue 10. 2020-06-08. PMID:31524631. |
previous studies revealed that terazosin (tz) enhances the activity of phosphoglycerate kinase 1 (pgk1), thereby stimulating glycolysis and increasing cellular atp levels. |
2020-06-08 |
2023-08-13 |
mouse |
| Penelope J Boyd, Wen-Yo Tu, Hannah K Shorrock, Ewout J N Groen, Roderick N Carter, Rachael A Powis, Sophie R Thomson, Derek Thomson, Laura C Graham, Anna A L Motyl, Thomas M Wishart, J Robin Highley, Nicholas M Morton, Thomas Becker, Catherina G Becker, Paul R Heath, Thomas H Gillingwate. Bioenergetic status modulates motor neuron vulnerability and pathogenesis in a zebrafish model of spinal muscular atrophy. PLoS genetics. vol 13. issue 4. 2017-06-01. PMID:28426667. |
conversely, pgk1 overexpression, or treatment with terazosin (an fda-approved small molecule that binds and activates pgk1), rescued motor axon phenotypes in sma zebrafish. |
2017-06-01 |
2023-08-13 |
mouse |
| Xinping Chen, Chunyue Zhao, Xiaolong Li, Tao Wang, Yizhou Li, Cheng Cao, Yuehe Ding, Mengqiu Dong, Lorenzo Finci, Jia-Huai Wang, Xiaoyu Li, Lei Li. Terazosin activates Pgk1 and Hsp90 to promote stress resistance. Nature chemical biology. vol 11. issue 1. 2015-02-25. PMID:25383758. |
terazosin activates pgk1 and hsp90 to promote stress resistance. |
2015-02-25 |
2023-08-13 |
Not clear |